Pfizer's Xalkori, Kyowa Hakko Kirin's Poteligeo And Others Receive Chuikyo Pricing
This article was originally published in PharmAsia News
Executive Summary
Kyowa Hakko Kirin's Poteligeo cleared for first global market launch, earning a 10% premium for added-value benefits.